WO2012093976A1 - A composition comprising ibandronate at least 50 % of a filling agent and a sweetener - Google Patents

A composition comprising ibandronate at least 50 % of a filling agent and a sweetener Download PDF

Info

Publication number
WO2012093976A1
WO2012093976A1 PCT/TR2012/000007 TR2012000007W WO2012093976A1 WO 2012093976 A1 WO2012093976 A1 WO 2012093976A1 TR 2012000007 W TR2012000007 W TR 2012000007W WO 2012093976 A1 WO2012093976 A1 WO 2012093976A1
Authority
WO
WIPO (PCT)
Prior art keywords
water soluble
formulations
formulation according
weight
soluble formulation
Prior art date
Application number
PCT/TR2012/000007
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2011/00151A external-priority patent/TR201100151A2/en
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012093976A1 publication Critical patent/WO2012093976A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention relates to water soluble formulations so as to be used in treatment and/or prevention of bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease, periprostatic bone loss, Paget' s disease, and production methods thereof.
  • bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease, periprostatic bone loss, Paget' s disease, and production methods thereof.
  • Bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, Paget' s disease are the most common diseases after cardiovascular diseases and cancer in the world.
  • Particularly osteoporosis is a stealthily progressive disease which affects postmenopausal women and arises when the bones are weakened and very susceptible to fracture because of low bone mass and deterioration of bone quality.
  • Osteoporosis is seen three times more likely in women than men; and the disease which is seen more common in old age is not a disease seen only in old age. Osteoporosis-related bone fractures have gradually become a serious public health concern.
  • the group of drugs frequently used in treatment of bone diseases including osteoporosis is bisphosphonates.
  • the bisphosphonate group of drugs causes decrease in number and activity of the cells called osteoclasts which are responsible for bone resorption; and by this means, they provide to preserve and even increase bone mass and strength.
  • the most common drugs of this group are alendronate, etidronate, risedronate, ibandronate and zoledronic acid.
  • Ibandronate (Formula I) is a potent third generation bisphosphonate. It is known that, when compared to placebo, ibandronate treatment wherein 2.5 mg daily ibandronate is administered to the patients with osteoporosis reduces risk for vertebral fracture in 3-year-period from approximately 10% to 5% and reduces risk for symptomatic vertebral fractures from 5.3 to 2.8%.
  • Ibandronate marketed under the trade names BONVIVA® and BONDRONAT® is in film coated tablet and intravenous forms.
  • Bisphosphonates generally have low bioavailability; therefore, it is recommended that orally used bisphosphonates are taken on an empty stomach.
  • Intravenous ibandronate is a form only used in treatment of cancer- related bone diseases.
  • the dosage used is a single dose in every 3-4 weeks though it changes according to the stage of the disease.
  • Oral ibandronate tablet form is not a good option for ibandronate which already has low bioavailability.
  • Intravenous form which was improved as an alternative to solid dosage forms is the most difficult treatment method to comply with for patients. Many patients, especially the group of patients over 50 years of age, do not want to take the drug in intravenous form which is administered with a sterile needle. Furthermore, intravenous dosage forms require an expert medical practitioner for administration and this situation is disadvantageous for patients. Many patients do not prefer intravenous administration due to these reasons.
  • the present invention discloses water soluble pharmaceutical formulations comprising ibandronate and/or its pharmaceutically acceptable salts, hydrates, amorphous or crystalline forms or the combinations thereof as active agent; production and usage areas thereof.
  • the purpose of the present invention is to produce easily drinkable, highly bioavailable and easy-to-use water soluble formulations wherein the bitter taste of the active agent is suppressed.
  • the characteristic feature of the water soluble formulations developed within the scope of the present invention is that the bitter taste can be suppressed without need for using high amounts of sweetener.
  • At least one sweetener is used in the range of 1 to 10% by weight, preferably in the range of 1 to 8% by weight, more preferably in the range of 1 to 5% by weight in the formulations.
  • sweeteners that can be used in the water soluble formulations of the present invention are selected from a group comprising aspartame, dextrose, fructose, sucralose, sodium cyclamate, mannitol, maltose, sorbitol, saccharin and/or pharmaceutically acceptable salts or the combinations thereof.
  • formulations of the present invention comprise at least one filling agent minimum 50% by weight, preferably in the range of 50 to 80 % by weight, more preferably in the range of 50 to 60 % by weight.
  • the filling agents that can be used in the formulations of the present invention are preferably from the group of water soluble sugar alcohols though they are selected from sorbitol, mannitol, xylitol, erythrol, isomalt, starch hydrolysates or the combinations thereof.
  • the ratio of the filling agent to the sweetener comprised in the formulations by weight is minimum 20, preferably in the range of 20 to 25.
  • Another characteristic feature of the formulations of the present invention is that the preferred filling agent is mannitol.
  • Another characteristic feature of the formulations of the present invention is that suitable substance combination and suitable ratios thereof are used for ibandronate formulations with suppressed bitter taste.
  • compositions of the present invention are basically composed of the components below;
  • Ibandronate sodium in the range of 10 to 90% by weight, preferably in the range of 10 to 70% by weight, more preferably in the range of 10 to 50% by weight;
  • At least one pharmaceutically acceptable filling agent minimum 50% by weight, preferably in the range of 50 to 80% by weight, more preferably in the range of 50 to 60% by weight.
  • At least one pharmaceutically acceptable sweetener in the range of 1 to 10 % by weight, preferably in the range of 1 to 8% by weight, more preferably in the range of 1 to 5 % by weight.
  • formulations of the present invention can optionally comprise at least one other pharmaceutically acceptable excipient in addition to the specified above.
  • the pharmaceutically acceptable excipients that can be used in the water soluble formulations of the present invention can be selected from a group comprising filling agents, binders, lubricants, disintegrants, diluents, stabilizing agents, sweeteners, taste regulating agents, inorganic salts, flavouring agents.
  • the inorganic salts that can be used in the formulations of the present invention can be selected from a group comprising sodium carbonate, sodium bicarbonate, sodium acetate, sodium chloride, potassium chloride, potassium carbonate, potassium bicarbonate.
  • the formulations of the present invention can comprise an inorganic salt in the range of 1 to 40% by weight, preferably in the range of 5 to 35% by weight, more preferably in the range of 8 to 33% by weight.
  • the inorganic salt preferred is selected from a group comprising sodium or potassium carbonates or bicarbonates.
  • the inorganic salt which is particularly preferred is sodium bicarbonate.
  • the diluents that can be used in the water soluble formulations of the present invention can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
  • the lubricants that can be used in the water soluble formulations of the present invention can be selected from a group comprising metallic stearates (such as magnesium stearate, calcium stearate, aluminium stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oil, leucine, polyethylene glycols, metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
  • metallic stearates such as magnesium stearate, calcium stearate, aluminium stearate
  • fatty acid esters such as sodium stearyl fumarate
  • fatty acids such as stearic acid
  • fatty alcohols glyceryl behenate
  • mineral oil paraffins
  • the disintegrants that can be used in the water soluble formulations of the present invention can be selected from a group comprising highly dispersive polymers, for instance cross linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate or combinations thereof.
  • highly dispersive polymers for instance cross linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate or combinations thereof.
  • the water soluble formulations of the present invention can optionally comprise flavouring agents; said flavouring agents can have banana flavour, strawberry flavour, lemon flavour, orange flavour, peach flavour, vanilla flavour or a similar natural fruit flavour or an aromatic plant flavour.
  • Ibandronate or its pharmaceutically acceptable salt used in the pharmaceutical formulations of the present invention is preferably ibandronate sodium salt.
  • active agent in monohydrate or dihydrate form can also be used.
  • formulations of the present invention comprise ibandronate sodium in the range of 50 to 300 mg, preferably in the range of 50 to 200 mg per unit dosage form.
  • Said dosage forms can be used once a month or at least once a day according to the type of the disease to be treated. For instance, in the case that the disease to be treated is osteoporosis, it is recommended for use once a month; in treatment/prevention of the diseases such as the tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease it is recommended for use at least once a day.
  • the dosage forms of the present invention are preferably taken as dissolved in sufficient amount water, preferably in 150 ml of water, preferably just before the first meal of the day. Dissolution time of the formulations of the present invention in 150 ml water is in the range of 15 to 60 seconds, preferably in the range of 15 to 45 seconds.
  • the water soluble formulations of the present invention can be formulated in powder or granule form and presented as filled into bottles, sachet as well as presented in tablet or capsule for obtainment of the dosage form required.
  • formulations of the present invention are formulated in powder form.
  • formulations of the present invention are formulated in granule form.
  • the dosage form preferred is prepared in sachet dosage form designed to prevent the active agent granules from being affected from the environmental factors such as heat, moisture, light.
  • Powder or granule formulations prepared within the scope of the present invention can be effervescent or non-effervescent; the formulations preferred are non-effervescent formulations.
  • formulations of the present invention can be produced by any methods in the prior art; these methods can be dry granulation, dry blending, direct compression or wet granulation.
  • the method preferred for production of the formulations of the present invention is dry blending method and this method is applied as follows;
  • the method to be used for production of ibandronate sodium sachet formulations given above is dry blending method which is described in the description part in detail.
  • the pharmaceutical powder formulation obtained by dry blending and sieving steps is sent to the sachet filling machine and final product is obtained in sachet form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to water soluble formulations so as to be used in treatment and/or prevention of bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease, periprostatic bone loss, Paget's disease; and production methods thereof.

Description

A COMPOSITION COMPRISING IBANDRONATE AT LEAST 50 % OF
A FILLING AGENT AND A SWEETENER
The present invention relates to water soluble formulations so as to be used in treatment and/or prevention of bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease, periprostatic bone loss, Paget' s disease, and production methods thereof.
The Prior Art
Bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, Paget' s disease are the most common diseases after cardiovascular diseases and cancer in the world. Particularly osteoporosis is a stealthily progressive disease which affects postmenopausal women and arises when the bones are weakened and very susceptible to fracture because of low bone mass and deterioration of bone quality. Osteoporosis is seen three times more likely in women than men; and the disease which is seen more common in old age is not a disease seen only in old age. Osteoporosis-related bone fractures have gradually become a serious public health concern.
The group of drugs frequently used in treatment of bone diseases including osteoporosis is bisphosphonates. The bisphosphonate group of drugs causes decrease in number and activity of the cells called osteoclasts which are responsible for bone resorption; and by this means, they provide to preserve and even increase bone mass and strength. The most common drugs of this group are alendronate, etidronate, risedronate, ibandronate and zoledronic acid.
Ibandronate (Formula I) is a potent third generation bisphosphonate. It is known that, when compared to placebo, ibandronate treatment wherein 2.5 mg daily ibandronate is administered to the patients with osteoporosis reduces risk for vertebral fracture in 3-year-period from approximately 10% to 5% and reduces risk for symptomatic vertebral fractures from 5.3 to 2.8%.
Figure imgf000002_0001
Formula (I)
Ibandronate marketed under the trade names BONVIVA® and BONDRONAT® is in film coated tablet and intravenous forms. Bisphosphonates generally have low bioavailability; therefore, it is recommended that orally used bisphosphonates are taken on an empty stomach.
Intravenous ibandronate, on the other hand, is a form only used in treatment of cancer- related bone diseases. The dosage used is a single dose in every 3-4 weeks though it changes according to the stage of the disease.
However, said dosage forms in the prior art cannot meet patient requirements effectively. Oral ibandronate tablet form is not a good option for ibandronate which already has low bioavailability.
Intravenous form which was improved as an alternative to solid dosage forms is the most difficult treatment method to comply with for patients. Many patients, especially the group of patients over 50 years of age, do not want to take the drug in intravenous form which is administered with a sterile needle. Furthermore, intravenous dosage forms require an expert medical practitioner for administration and this situation is disadvantageous for patients. Many patients do not prefer intravenous administration due to these reasons.
As seen, there is need for highly bioavailable new approaches which appeal to a wider profile of patients for pharmaceutical formulations comprising ibandronate.
The inventors have achieved to produce water soluble ibandronate sodium formulations within the scope of the present invention in line with this need in the prior art.
However, the important problem related to these water soluble formulations is that patients do not want to drink the formulations due to the bitter taste of the active agent.
This problem has been surprisingly solved by selection of the types of the filling agent and the sweetener used in the formulations and adjusting the amounts of these in the formulations.
Masking the bitter taste in this way without need for using high amounts of sweetener enables that the water soluble formulations appeal to a wider profile of patients (for instance diabetic patients). ■■. / - . ' J IM
Detailed Description of the Invention
The present invention discloses water soluble pharmaceutical formulations comprising ibandronate and/or its pharmaceutically acceptable salts, hydrates, amorphous or crystalline forms or the combinations thereof as active agent; production and usage areas thereof.
The purpose of the present invention is to produce easily drinkable, highly bioavailable and easy-to-use water soluble formulations wherein the bitter taste of the active agent is suppressed.
The characteristic feature of the water soluble formulations developed within the scope of the present invention is that the bitter taste can be suppressed without need for using high amounts of sweetener.
One characteristic feature of the formulations of the present invention is that at least one sweetener is used in the range of 1 to 10% by weight, preferably in the range of 1 to 8% by weight, more preferably in the range of 1 to 5% by weight in the formulations.
The sweeteners that can be used in the water soluble formulations of the present invention are selected from a group comprising aspartame, dextrose, fructose, sucralose, sodium cyclamate, mannitol, maltose, sorbitol, saccharin and/or pharmaceutically acceptable salts or the combinations thereof.
Another characteristic feature of the formulations of the present invention is that the formulations comprise at least one filling agent minimum 50% by weight, preferably in the range of 50 to 80 % by weight, more preferably in the range of 50 to 60 % by weight.
The filling agents that can be used in the formulations of the present invention are preferably from the group of water soluble sugar alcohols though they are selected from sorbitol, mannitol, xylitol, erythrol, isomalt, starch hydrolysates or the combinations thereof.
One characteristic feature of the water soluble formulations of the present invention is that the ratio of the filling agent to the sweetener comprised in the formulations by weight is minimum 20, preferably in the range of 20 to 25.
Another characteristic feature of the formulations of the present invention is that the preferred filling agent is mannitol. Another characteristic feature of the formulations of the present invention is that suitable substance combination and suitable ratios thereof are used for ibandronate formulations with suppressed bitter taste.
The pharmaceutical formulations of the present invention are basically composed of the components below;
1. Ibandronate sodium in the range of 10 to 90% by weight, preferably in the range of 10 to 70% by weight, more preferably in the range of 10 to 50% by weight;
2. At least one pharmaceutically acceptable filling agent minimum 50% by weight, preferably in the range of 50 to 80% by weight, more preferably in the range of 50 to 60% by weight.
3. At least one pharmaceutically acceptable sweetener in the range of 1 to 10 % by weight, preferably in the range of 1 to 8% by weight, more preferably in the range of 1 to 5 % by weight.
The formulations of the present invention can optionally comprise at least one other pharmaceutically acceptable excipient in addition to the specified above.
The pharmaceutically acceptable excipients that can be used in the water soluble formulations of the present invention can be selected from a group comprising filling agents, binders, lubricants, disintegrants, diluents, stabilizing agents, sweeteners, taste regulating agents, inorganic salts, flavouring agents.
The inorganic salts that can be used in the formulations of the present invention can be selected from a group comprising sodium carbonate, sodium bicarbonate, sodium acetate, sodium chloride, potassium chloride, potassium carbonate, potassium bicarbonate.
The formulations of the present invention can comprise an inorganic salt in the range of 1 to 40% by weight, preferably in the range of 5 to 35% by weight, more preferably in the range of 8 to 33% by weight. The inorganic salt preferred is selected from a group comprising sodium or potassium carbonates or bicarbonates. The inorganic salt which is particularly preferred is sodium bicarbonate.
The diluents that can be used in the water soluble formulations of the present invention can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
The lubricants that can be used in the water soluble formulations of the present invention can be selected from a group comprising metallic stearates (such as magnesium stearate, calcium stearate, aluminium stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oil, leucine, polyethylene glycols, metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
The disintegrants that can be used in the water soluble formulations of the present invention can be selected from a group comprising highly dispersive polymers, for instance cross linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate or combinations thereof.
The water soluble formulations of the present invention can optionally comprise flavouring agents; said flavouring agents can have banana flavour, strawberry flavour, lemon flavour, orange flavour, peach flavour, vanilla flavour or a similar natural fruit flavour or an aromatic plant flavour.
Ibandronate or its pharmaceutically acceptable salt used in the pharmaceutical formulations of the present invention is preferably ibandronate sodium salt. Optionally, active agent in monohydrate or dihydrate form can also be used.
One characteristic feature of the formulations of the present invention is that said formulations comprise ibandronate sodium in the range of 50 to 300 mg, preferably in the range of 50 to 200 mg per unit dosage form.
Said dosage forms can be used once a month or at least once a day according to the type of the disease to be treated. For instance, in the case that the disease to be treated is osteoporosis, it is recommended for use once a month; in treatment/prevention of the diseases such as the tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease it is recommended for use at least once a day. The dosage forms of the present invention are preferably taken as dissolved in sufficient amount water, preferably in 150 ml of water, preferably just before the first meal of the day. Dissolution time of the formulations of the present invention in 150 ml water is in the range of 15 to 60 seconds, preferably in the range of 15 to 45 seconds.
The water soluble formulations of the present invention can be formulated in powder or granule form and presented as filled into bottles, sachet as well as presented in tablet or capsule for obtainment of the dosage form required.
One characteristic feature of the formulations of the present invention is that the formulations are formulated in powder form.
Another characteristic feature of the formulations of the present invention is that the formulations are formulated in granule form.
The dosage form preferred is prepared in sachet dosage form designed to prevent the active agent granules from being affected from the environmental factors such as heat, moisture, light.
Powder or granule formulations prepared within the scope of the present invention can be effervescent or non-effervescent; the formulations preferred are non-effervescent formulations.
The formulations of the present invention can be produced by any methods in the prior art; these methods can be dry granulation, dry blending, direct compression or wet granulation.
The method preferred for production of the formulations of the present invention is dry blending method and this method is applied as follows;
1. Mixing ibandronate sodium, at least one pharmaceutically acceptable filling agent, at least one sweetener and at least one inorganic salt,
2. Sieving the mixture,
3. Sending the mixture to the related filling machines for obtainment of the dosage form required. The examples of the formulations of the present invention are given below. The formulations of the present invention are not limited to these examples.
EXAMPLES
Example I. Sachet Formulation
Figure imgf000009_0001
Example II. Sachet Formulation
Figure imgf000009_0002
The method to be used for production of ibandronate sodium sachet formulations given above is dry blending method which is described in the description part in detail.
The pharmaceutical powder formulation obtained by dry blending and sieving steps is sent to the sachet filling machine and final product is obtained in sachet form.

Claims

1. A water soluble formulation comprising ibandronate or its salts, hydrates, amorphous or crystalline forms or combinations thereof characterized in that the formulations comprise at least one pharmaceutically acceptable filling agent minimum 50% by weight and at least one pharmaceutically acceptable sweetener in the range of 1 to 10 % by weight.
2. The water soluble formulation according to claim 1 characterized in that the formulations comprise at least one pharmaceutically acceptable filling agent minimum in the range of 50 to 80% by weight and at least one pharmaceutically acceptable sweetener in the range of 1 to 8% by weight.
3. The water soluble formulation according to claims 1-2 characterized in that the formulations comprise at least one pharmaceutically acceptable filling agent minimum in the range of 50 to 60% by weight and at least one pharmaceutically acceptable sweetener in the range of 1 to 5% by weight.
4. The water soluble formulation according to claims 1-3 characterized in that the filling agent is selected from the group of sugar alcohols comprising sorbitol, mannitol, xylitol, erythrol, isomalt, starch hydrolysates or combinations thereof.
5. The water soluble formulation according to claims 1-3 characterized in that the sweetener is selected from a group comprising aspartame, dextrose, fructose, sucralose, sodium cyclamate, mannitol, maltose, sorbitol, saccharin and/or pharmaceutically acceptable salts or combinations thereof.
6. The water soluble formulation according to claim 4 characterized in that the filling agent is mannitol.
7. The water soluble formulation according to claims 1-6 characterized in that the ratio of the filling agent to the sweetener comprised in the formulations by weight is minimum 20.
8. The water soluble formulation according to claim 7 characterized in that the ratio of the filling agent to the sweetener comprised in the formulations by weight is in the range of 20 to 25.
9. The water soluble formulation according to any preceding claims characterized in that the formulation comprises at least one pharmaceutically acceptable excipient selected from a group comprising filling agents, binders, lubricants, disintegrants, diluents, stabilizing agents, sweeteners, taste regulating agents, inorganic salts, flavouring agents.
10. The water soluble formulation according to any preceding claims characterized in that the formulation is in powder or granule form.
11. The water soluble formulation according to claim 10 characterized in that said formulations are filled into bottles, capsules, sachet or compressed in tablet form for obtainment of the required dosage form.
12. The water soluble formulation according to claim 11 characterized in that the formulations are in sachet form.
13. The water soluble formulation according to claim 1 characterized in that the formulation is used in treatment and/or prevention of bone diseases such as hypercalcaemia, osteoporosis, tumoral osteolysis, malignant hypercalcaemia, metastatic bone disease, periprostatic bone loss, Paget' s disease.
PCT/TR2012/000007 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener WO2012093976A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2011/00151 2011-01-06
TR2011/00151A TR201100151A2 (en) 2011-01-06 2011-01-06 Ibandronate formulation.
TR2011/10525A TR201110525A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.
TR2011/10525 2011-10-24

Publications (1)

Publication Number Publication Date
WO2012093976A1 true WO2012093976A1 (en) 2012-07-12

Family

ID=45722687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener

Country Status (2)

Country Link
TR (1) TR201110525A2 (en)
WO (1) WO2012093976A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
WO2010117346A2 (en) * 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
WO2010117346A2 (en) * 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility

Also Published As

Publication number Publication date
TR201110525A2 (en) 2012-07-23

Similar Documents

Publication Publication Date Title
ES2313735T3 (en) ORAL PHARMACEUTICAL PREPARATION CONTAINING IBANDRONATE.
AU712710B2 (en) Effervescent bisphosphonate formulation
US20030158154A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
RU2405541C2 (en) Pharmaceutical copmositions dissolving in oral cavity
CN100592909C (en) Dosage form of sodium ibuprofen
JP2005516928A (en) Bisphosphonate liquid formulation for bone abnormalities
WO2010090614A1 (en) Pharmaceutical formulation comprising risedronate, calcium carbonate and vitamin d3 combined in a single dosage form
EP2575796A1 (en) Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
WO2010101537A1 (en) Pharmaceutical composition of alendronate and a calcium salt combined in a single dosage form
US9044401B2 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
EP2575758A1 (en) Formulation for osteoporosis
CA2671727C (en) A composition containing a bisphosphonic acid in combination with vitamin d
CZ287984B6 (en) Tablet with enhanced biological availability of active substance i.e. clodronic acid and process for preparing thereof
EP1651191B1 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
US20130164342A1 (en) Formulations for osteoporosis
WO2012093976A1 (en) A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
WO2012093975A1 (en) Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight
WO2012093977A1 (en) Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
SI21403A (en) Pharmaceutical form with alendronic acid, its salts or esters and procedure for its preparation
EP2661262B1 (en) Improved bisphosphonate formulations
WO2010090613A1 (en) The combined pharmaceutical composition in a single dosage form
EP2661258B1 (en) Improved risedronate formulation
WO2012124982A2 (en) Oral preparation having an enteric coating
CN110604309A (en) Nutritional supplement for assisting in preventing osteoporosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12705176

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12705176

Country of ref document: EP

Kind code of ref document: A1